Xcout Intel
HEXIMA LIMITED. competitors & alternatives
The 12 closest competitors and alternatives to HEXIMA LIMITED. among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what HEXIMA LIMITED. actually does, not by market-cap band.
Subscribe to see HEXIMA LIMITED.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About HEXIMA LIMITED.
Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
HEXIMA LIMITED. at a glance
HEXIMA LIMITED. is a pharmaceuticals, biotechnology & life sciences company headquartered in Preston, Australia. Xcout tracks 11 named people at HEXIMA LIMITED., including Thomas C. Gentile (Chief Executive Officer, President & Chairman).
HEXIMA LIMITED. leadership
- Thomas C. GentileChief Executive Officer, President & Chairman
- Lyndon SmithPresident of Americas & Global Fibers
- Lilian Regis BraylePresident of Aerospace - Europe, MEA/AP & Industrial
- James G. CooganExecutive Vice President & Chief Financial Officer
- Bob KodySenior Vice President & Chief Technology Officer
- Gail Eileen LehmanExecutive Vice President, Chief Legal & Sustainability Officer and Secretary
5 more named people on record for HEXIMA LIMITED., with roles, board committees and tenure — see the full roster →
Top 12 HEXIMA LIMITED. competitors
Ranked by semantic similarity — how close each company is to HEXIMA LIMITED. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Pharmaceuticals
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
Similar pharmaceuticals, biotechnology & life sciences company
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of HEXIMA LIMITED. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for HEXIMA LIMITED.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →